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Abstract
Aims/hypothesis Islet-specific autoantibodies can predict the development of type 1 diabetes. However, it remains unclear if B
cells, per se, contribute to the causal pancreatic immunopathology. We aimed to identify phenotypic signatures of disease
progression among naive and memory B cell subsets in the peripheral blood of individuals with type 1 diabetes.
Methods A total of 69 participants were recruited across two separate cohorts, one for discovery purposes and the other for
validation purposes. Each cohort comprised two groups of individuals with type 1 diabetes (one with newly diagnosed type 1
diabetes and the other with long-standing type 1 diabetes) and one group of age- and sex-matched healthy donors. The pheno-
typic characteristics of circulating naive and memory B cells were investigated using polychromatic flow cytometry, and serum
concentrations of various chemokines and cytokines were measured using immunoassays.
Results A disease-linked phenotype was detected in individuals with long-standing type 1 diabetes, characterised by reduced C-X-C
motif chemokine receptor 3 (CXCR3) expression on switched (CD27+IgD−) and unswitched (CD27intermediateIgD+) memory B cells.
These changes were associatedwith raised serum concentrations of B cell activating factor and of the CXCR3 ligands, chemokine (C-
X-C motif) ligand (CXCL)10 and CXCL11. A concomitant reduction in CXCR3 expression was also identified on T cells.
Conclusions/interpretation Our data reveal a statistically robust set of abnormalities that indicate an association between type 1
diabetes and long-term dysregulation of a chemokine ligand/receptor system that controls B cell migration.
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Abbreviations
BAFF B cell activating factor
CXCL Chemokine (C-X-C motif) ligand
CXCR3 C-X-C motif chemokine receptor 3
IQR Interquartile range
MFI Median fluorescence intensity
PBMC Peripheral blood mononuclear cell
SPADE Spanning-tree progression analysis of density-
normalised events
Introduction
Type 1 diabetes is a multifactorial autoimmune disorder trig-
gered by islet antigen-specific CD4+ and CD8+ T cell-
mediated destruction of insulin-producing cells in the pancre-
as. Although the presence of various autoantibodies can pre-
dict the onset of type 1 diabetes, it remains unclear if the
corresponding autoreactive B cells play a determinative role
in the underlying immunopathology. Clinical studies have
shown that B cell depletion with rituximab temporarily slows
the decline of C-peptide levels in the blood of individuals with
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type 1 diabetes [1]. Moreover, B cells are present in the pan-
creatic islets at the time of diagnosis [2] and persist in situ
throughout the course of disease [3].
A previous study identified transitional CD27−IgD+IgM−
B cell expansions in individuals with type 1 diabetes and
healthy carriers of the PTPN22 genetic variant 1858T, which
predisposes to a variety of autoimmune disorders [4]. In
contrast, no disease-specific alterations in the B cell compart-
ment were detected in another study, designed to quantify the
expression levels of CD19, CD24, CD27, CD38, IgD and
IgM in individuals with type 1 diabetes and age- and
sex-matched healthy donors [5]. Equivalent results were
obtained in a comprehensive analysis of children with
newly diagnosed type 1 diabetes compared with healthy
control individuals [6]. However, increased frequencies of
marginal zone CD19+CD21+CD23− B cells and decreased
frequencies of regulatory CD1d+CD5+CD19+ and follicular
CD19+CD21−CD23+ B cells have been reported in Chinese
individuals with type 1 diabetes [7]. Similarly, decreased
frequencies of CD40+ and interleukin (IL)-10+ B cells were
detected in another cohort of individuals with type 1
diabetes relative to healthy donors [8]. In addition, high-
affinity insulin-binding naive B cells are lost from the
anergic compartment in individuals with newly diagnosed
type 1 diabetes, but return in individuals with long-standing
type 1 diabetes [9]. Thus, whilst differences are present in
those with type 1 diabetes compared with healthy individuals,
a consistent disease-relevant phenotype in the circulating B
cell pool has not been delineated.
To inform this ongoing debate, we conducted an extensive
flow cytometric analysis of B cell subsets in individuals with
type 1 diabetes and age- and sex-matched healthy donors.
Methods
Study design and setting This study was designed to compare
the phenotypes of circulating B and T cells (using flow cy-
tometry to analyse cell-surface markers) and levels of serum
chemokines and cytokines in healthy donors and people with
newly diagnosed or long-standing type 1 diabetes. Venous
blood samples were collected from individuals in South
Wales between 2012 and 2014. Peripheral blood mononuclear
cells (PBMCs) were analysed in two batches (2013 and 2014).
Serum samples were cryopreserved and analysed as a single
batch.
Participants Adults with newly diagnosed or long-standing
type 1 diabetes were recruited for this study, together with
age- and sex-matched healthy donors (age was matched to
±2 years). Type 1 diabetes was diagnosed according to criteria
established by the American Diabetes Association [10].
Insulin treatment was commenced within 1 month of diagno-
sis. Time from diagnosis was categorised as less than 1 year
for newly diagnosed individuals and more than 3 years for
those with long-standing diabetes. Age- and sex-matched
healthy donors were seronegative for islet-specific autoanti-
bodies, with no personal or family history of type 1 diabetes or
other autoimmune conditions. The discovery cohort (StudyA)
included n = 10 newly diagnosed individuals (mean age
33.4 years, range 23–44 years), n = 10 individuals with long-
standing diabetes (mean age 40.2 years, range 29–50 years)
and n = 15 healthy donors (mean age 38.2 years, range 24–
50 years). The validation cohort (Study B) included n = 10
newly diagnosed individuals (mean age 24.3 years, range
19–34 years), n = 10 individuals with long-standing diabetes
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(mean age 38.5 years, range 23–48 years) and n = 14 healthy
donors (mean age 32.5 years, range 22–48 years). Additional
participants were recruited for immunoassay analysis of serum
chemokines and cytokines (n = 34 newly diagnosed individ-
uals; n = 21 individuals with long-standing diabetes; n = 33
healthy donors, not matched). Cohort details are summarised
in electronic supplementary material (ESM) Tables 1–3.
Ethics This study was approved by the South East Wales
Research Ethics Committee and conducted in accordance with
the principles of Good Clinical Practice established by the
International Council for Harmonisation and the World
Health Organization. All participants provided written in-
formed consent prior to enrolment, as mandated by the
Declaration of Helsinki.
Islet-specific autoantibodies Serum autoantibodies specific
for GAD, islet antigen-2 and zinc transporter-8 were quanti-
fied by ELISA (RSR, Cardiff, UK). Positive thresholds were
set at 5 U/ml for GAD, 7.5 U/ml for islet antigen-2 and 15 U/
ml for zinc transporter-8.
HLA class II genotyping Genomic DNA was extracted from
whole blood samples collected in EDTA. HLA-DRB alleles
(DRB1*0101-0103, DRB1*1501-1505, DRB1*1601-1606,
DRB1*0301 , DRB1*0401-0422 , DRB1*1101-1121 ,
DRB1*1201-1203, DRB1*1302-1305/DRB1*1303-1304,
DRB1*1401/1404/1405, DRB1*0701-0702, DRB1*0805-
0801, DRB1*0901, DRB1*1001, DRB3*0101-0301 and
DRB4*0101) were resolved using PCRs with sequence-
specific primers [11] (ESM Table 4).
Blood samples PBMCs were isolated from heparinised sam-
ples of whole blood via density gradient centrifugation using
Lymphoprep (STEMCELL Technologies, Cambridge, UK).
Aliquots of 5–20 × 106 PBMCs/ml per vial were stored in
liquid nitrogen after cooling overnight to −80°C at a con-
trolled rate of −1°C/min in 90% AIM-V medium (Thermo
Fisher Scientific, Hemel Hempstead, UK) supplemented with
10% dimethyl sulfoxide (Sigma-Aldrich, Gillingham, UK)
(vol./vol.).
Flow cytometry Thawed PBMCswere blocked using TruStain
(BioLegend, San Diego, CA, USA) for 5 min at room temper-
ature, stained with LIVE/DEAD Fixable Aqua (Thermo
Fisher Scientific) for 10 min at room temperature and labelled
with titrated concentrations of the following monoclonal anti-
bodies for 30 min at 4°C: α-CD19-PE-Cy7 (clone SJ25C1)
and α-CD24-APC-eFluor780 (clone SN3) (both from
eBioscience, San Diego, CA, USA); α-CD3-BV711 (clone
OKT3), α-CD45R/B220-BV421 (clone RA3-6B2) and α-
IgD-AF488 (clone IA6-2) (all from BioLegend); α-CD27-
Q605 (clone CLB-27/1) (Thermo Fisher Scientific); α-
CD21-PE-Cy5 (clone B-ly4), α-CD38-PE-CF594 (clone
HIT2) and α-C-X-C motif chemokine receptor 3 (CXCR3)-
PE (clone IC6/CXCR3) (all from BD Biosciences, Franklin
Lakes, NJ, USA); and α-CD95-APC (clone DX2) (Miltenyi
Biotec, Bergisch Gladbach, Germany). Cells were then
washed in PBS containing 0.5% BSA (wt/vol.) and 2 mmol/l
EDTA, fixed with 1% paraformaldehyde (wt/vol.) and acquired
using a special-order system FACSAria II flow cytometer (BD
Biosciences). Further details are available in ESMTable 5. Data
were acquired in a blinded fashion and analysed using FlowJo
software version 10 (Tree Star, Ashland, OR, USA).
Spanning-tree progression analysis of density-normalised
events Live B cells were identified in serial gates as singlets,
lymphocytes, LIVE/DEAD Fixable Aqua−, CD3− and CD19+
events using FlowJo software version 10. Compensated flow
cytometry standard files were exported and concatenated for
spanning-tree progression analysis of density-normalised
events (SPADE) using fixed settings (K-means algorithm,
100 clusters and arcsinh transformation with cofactor 150) in
SPADE software version 3.0 (http://pengqiu.gatech.edu/
software/SPADE/) [12, 13]. The following markers were
included in the analysis: CD19, CD21, CD24, CD27, CD38,
CD95, B220, CXCR3 and IgD. Auto-partitioning was used to
divide the resulting trees into eight areas. Median expression
of each marker was calculated for each donor in each node.
Data from the two cohorts were tested for normality and then
analysed separately because of differences in flow cytometer
set-up between Study A and Study B. As the data were nor-
mally distributed, an unpaired Student’s t test was used to
compare the transformed median fluorescence intensity
(MFI) of each marker in each area for newly diagnosed indi-
viduals and those with long-standing diabetes vs healthy do-
nors in Study A. The analysis was repeated in Study B for
markers identified as significantly different in newly diag-
nosed individuals and those with long-standing diabetes rela-
tive to healthy donors in Study A. In a final step, B cells were
gated manually, using FlowJo software version 10, to confirm
differences in MFI for each marker of interest, and signifi-
cance was assessed using a one-way ANOVAwith Dunnett’s
post hoc test.
Serum chemokines/cytokines Serum samples were analysed
using the U-PLEX platform (Meso Scale Diagnostics,
Rockville, MD, USA) to quantify chemokine (C-X-C motif)
ligand (CXCL)10, CXCL11, IL-4, IL-6, IL-10 and IFN-γ or
using DuoSet ELISA kits to quantify CXCL9, B cell activat-
ing factor (BAFF) and TGF-β (R&D Systems, Abingdon,
UK). Data were analysed using the Kruskal–Wallis test with
Dunn’s post hoc test.
Statistics As there were no existing data to guide power cal-
culations, and given the large number of variables under
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consideration, together with the modes of analysis we
planned to employ simultaneously across all groups of
participants, sample sizes were determined in part by fea-
sibility. Significant results from Study A were treated as
hypothesis-generating and tested for validation purposes
in Study B. An unpaired Student’s t test was used to
assess differences in mean values between two groups.
One-way ANOVA (for normally distributed data) or the
Kruskal–Wallis test (for non-normally distributed data) were
used with corrections for multiple comparisons to assess dif-
ferences in mean values between three or more groups. All
statistical tests were performed using Prism software version 6
(GraphPad, San Diego, CA, USA).
Results
CXCR3 expression is reduced on memory B cells in individuals
with type 1 diabetes To evaluate the phenotypic characteris-
tics of naive and memory B cells in individuals with type 1
diabetes, we developed a polychromatic flow cytometry panel
incorporating a viability dye and monoclonal antibodies spe-
cific for CD3, CD19, CD21, CD24, CD27, CD38, CD45R/
B220, CD95, CXCR3 and IgD. This panel was used to stain
PBMCs from individuals with type 1 diabetes (categorised as
newly diagnosed or long-standing) and healthy donors
assigned randomly to separate cohorts for discovery (Study
A) and validation (Study B). The data were then concatenated
and analysed using SPADE.
In contrast to manual analyses of high-dimensional flow
cytometry data, which may be subject to bias and user error,
SPADE is a form of multivariate analysis that automatically
groups closely related cells into clusters, also termed ‘nodes’,
based on the expression pattern of all selected markers [14].
These clusters are reduced to a two-dimensional visual
representation in which areas containing cells with similar
phenotypes and marker expression are automatically
partitioned. Using this approach, we identified eight pheno-
typically distinct B cell populations (Fig. 1a). The SPADE
analysis first identified two areas of naive cells (CD27−IgD+),
each of which had distinct expression of other markers (only
markers that differed between the two areas are listed, with
box-plots of each marker shown in Fig. 1b): area 1 cells were
CD19+CD21−CD24++CD38++, and area 4 cells were
CD19++CD21+CD24+CD38+. Second, there were two clusters
of switched CD27+IgD− memory cells: area 2 cells were
CXCR3++, and area 7 cells were CXCR3−. Third, two further
areas of switched CD27−IgD− memory cells were identified:
area 5 cells were CD19++CD21+CD38+CD95−B220+, and area
8 cells were CD19+CD21−CD38−CD95+B220−. Finally, there
were two clusters of unswitched CD27intermediate(int)IgD+ B cells
(area 3 cells were CD21−/+B220+CXCR3+, and area 6 cells
were CD21+B220−CXCR3−). The MFI of each marker was
then determined in each area for each sample (Fig. 1b), and
unpaired Student’s t tests were used to compare area-specific
differences in the expression of each marker between each di-
abetes group and healthy donors, with the main difference be-
ing found in CXCR3 (Fig. 1c). Non-significant results in Study
A were excluded from the analysis in Study B. This strategy
was adopted to minimise type 1 errors arising from multiple
comparisons. Moreover, we only accepted results where a
significant difference in Study Awas replicated in Study B.
Statistical analysis of area 2, which comprised switchedmem-
ory B cells with a CD21+CD24+CD27+CD38intCD95+IgD− phe-
notype (Fig. 1a), revealed that CXCR3 expression was reduced
in individuals with long-standing diabetes relative to healthy do-
nors in Study A (p < 0.05) and Study B (p< 0.005; Fig. 1c). A
similar pattern was observed for newly diagnosed individuals
relative to healthy donors in Study A (p< 0.05; Fig. 1c), with a
non-significant trend to reduced levels in Study B (p = 0.07).
These changes were further visualised by displaying the intensity
of CXCR3 expression in individuals with long-standing diabetes
vs healthy donors (Fig. 1d) and by overlaying histograms of
CXCR3 expression in area 2 (Fig. 1e). No significant correlation
was observed between CXCR3 expression levels and the pres-
ence of HLA-DRB1*03 or HLA-DRB1*04 in healthy donors
(data not shown).
In similar analyses, we found decreased levels of CD24 ex-
pression on switched CD21+CD24+CD27+CD38intCD95+IgD−
memory B cells (area 2) in newly diagnosed individuals and
those with long-standing diabetes vs healthy donors (newly di-
agnosed individuals: p < 0.01 in Study A, p < 0.01 in Study B;
individuals with long-standing diabetes: p < 0.05 in Study A, p
< 0.005 in Study B; Fig. 1f). Other significant differences were
also noted across both datasets in the diabetes groups compared
with healthy donors (Fig. 2). In particular, CXCR3 expression
was reduced on unswitched CD27intIgD+ memory B cells (area
3) in individuals with long-standing diabetes vs healthy donors
(p < 0.01 in Study A, p < 0.01 in Study B), CD45R/B220 ex-
pressionwas reduced on both unswitched CD27intIgD+memory
B cells (area 3: p < 0.005 in Study A, p < 0.005 in Study B) and
naive CD27−IgD+B cells (area 4: p < 0.05 in StudyA, p < 0.005
in Study B), and CD95 expression was reduced on switched
CD27+IgD− memory B cells (area 7: p < 0.05 in Study A, p <
0.01 in Study B). Furthermore, in individuals with newly diag-
nosed diabetes, CD24 expression was reduced on unswitched
CD27intIgD+ memory B cells (area 6: p < 0.01 in Study A, p <
0.05 in Study B).
To confirm these findings, we quantified expression levels
of CXCR3 and CD24 on switched CD27+IgD− memory B
cells using a manual gating strategy implemented with
FlowJo software (Fig. 3). A clear reduction in MFI was
observed for CXCR3 expression in individuals with long-
standing diabetes vs healthy donors (p < 0.01 in Study A,
p < 0.005 in Study B; Fig. 3a). In contrast, CD24 expression
was only reduced in Study B (p < 0.01; Fig. 3b).
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CXCR3 and CD38 expression are reduced on T cells in individ-
uals with type 1 diabetes A parallel analysis of CD3+ T cells
revealed that CXCR3 expression was reduced in four of the
eight areas identified by SPADE (Fig. 4a, b) in individuals
with long-standing diabetes vs healthy donors (areas 2, 4, 5
and 6: p < 0.005 in Study A, p < 0.005 in Study B; Fig. 4c–f).
High expression levels of CD38 accompanied high expression
levels of CXCR3 in area 4 (Fig. 4g). In both area 4
(CD38hiCXCR3hi) and area 6 (CD38intCXCR3hi), CD38 ex-
pression was reduced in individuals with long-standing diabe-
tes vs healthy donors (area 4: p < 0.05 in Study A, p < 0.005 in
Study B; area 6: p < 0.05 in Study A, p < 0.05 in Study B; Fig.
4i, j), whereas in area 3 (CXCR3lo), CD38 expression was
increased in newly diagnosed individuals vs healthy donors
(p < 0.05 in Study A, p < 0.005 in Study B; Fig. 4h). The
frequency of CD3+ T cells in area 4 was also lower in individ-
uals with long-standing diabetes vs healthy donors (p < 0.05
in Study A, p < 0.05 in Study B; Fig. 4k).
These findings were confirmed using a manual gating strat-
egy, which showed that CXCR3 expression was reduced on
CD3+ T cells in individuals with long-standing diabetes vs
healthy donors (p < 0.01 in Study A, p < 0.01 in Study B;
Fig. 3c). The frequency of CD3+CD38hiCXCR3hi T cells
was also lower in individuals with long-standing type 1 dia-
betes vs healthy donors (p < 0.05 in Study A, p < 0.05 in
Study B; Fig. 3d).
CXCR3 ligand concentrations are increased in individuals with
type 1 diabetes To shed light on these phenotypic changes, we
measured serum levels of the CXCR3 ligands CXCL9,
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Fig. 1 Automated phenotypic analysis of B cells. (a) SPADE image of
pooled B cells from all participants, auto-partitioned into eight annotated
areas with node size scaled to the log number of cells in each node,
showing median CXCR3 expression (transformed values in SPADE
using arcsinh transformation with cofactor 150) as a heatmap.
Annotated areas: 1. naive (CD27–IgD+); 2. switched memory
(CD27+IgD–); 3. unswitched (CD27intIgD+); 4. naive (CD27–IgD+); 5.
switched (CD27–IgD–); 6. unswitched (CD27intIgD+); 7. switched mem-
ory (CD27+IgD–); 8. switched (CD27-IgD–). (b) Box plots of marker
distribution in each area (or in all areas [All]) for the pooled samples
depicted in (a) (central lines indicate medians, and outer lines indicate
IQRs). (c) CXCR3 expression (transformed values) in area 2 for each
individual. (d) SPADE image of pooled B cells from all participants,
auto-partitioned into eight annotated areas (as in a) with node size scaled
to the log number of cells in each node, showing the ratio of median
CXCR3 expression (individuals with long-standing diabetes:healthy do-
nors; transformed values) in Study B. (e) Histogram overlays of CXCR3
expression in area 2 for Studies A and B. Orange, newly diagnosed
individuals; blue, individuals with long-standing diabetes; grey, healthy
donors. (f) CD24 expression (transformed values) in area 2 for each
individual. *p < 0.05, **p < 0.01, †p < 0.005, Student’s t test. AU, arbi-
trary units; HD, healthy donor; ND, newly diagnosed diabetes; LS, long-
standing diabetes. Means ± SEM are shown
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CXCL10 and CXCL11, together with IL-4, IL-6, IL-10,
IFN-γ, TGF-β and BAFF, which modulates the chemotactic
properties of B cells to other chemokines [15, 16]. It is also
notable that altered expression of the BAFF receptor has been
reported in children with type 1 diabetes [15, 16]. Serum con-
centrations of CXCL10 and CXCL11 were significantly in-
creased in newly diagnosed individuals and those with long-
standing diabetes vs healthy donors (CXCL10: p < 0.005 for
newly diagnosed individuals vs healthy donors, p < 0.01 for
individuals with long-standing diabetes vs healthy donors;
CXCL11: p < 0.05 for newly diagnosed individuals vs healthy
donors, p < 0.05 for individuals with long-standing diabetes
vs healthy donors; Fig. 5a, b). In contrast, serum concentra-
tions of CXCL9 were generally low, with no significant dif-
ferences among participant groups (Fig. 5c). Serum concen-
trations of BAFF were significantly increased in individuals
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Fig. 3 Conventional phenotypic
analysis of B and T cells.
Manually gated
CD27+CXCR3+IgD− B cells
were analysed for expression of
(a) CXCR3 and (b) CD24. (c)
Manually gated CXCR3+ T cells
were analysed for expression of
CXCR3. (d) Manually gated
CD38+CXCR3+ T cells were
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one-way ANOVAwith Dunnett’s
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calculated in FlowJo (not
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are shown
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with long-standing diabetes vs healthy donors (p < 0.01; Fig.
5d). There were no significant differences among groups with
respect to serum concentrations of IL-4, IL-6, IL-10, IFN-γ or
TGF-β (data not shown).
Discussion
The generation of memory B cells from naive precursors is
critical for the induction and maintenance of protective anti-
body responses to infectious agents [17]. Substantial pheno-
typic heterogeneity exists among memory B cells, and in var-
ious autoimmune conditions, such as rheumatoid arthritis and
systemic lupus erythematosus, altered subset profiles correlate
with disease activity [18]. However, few such associations
have been described in individuals with type 1 diabetes.
In this study, we examined the phenotypic characteristics of
naive and memory B cells in adults with type 1 diabetes and
age- and sex-matched healthy donors. Our data showed that
CXCR3 expression was reduced on memory B cells in indi-
viduals with long-standing diabetes. These changes were as-
sociated with raised serum concentrations of BAFF and the
CXCR3 ligands CXCL10 and CXCL11. In line with previous
studies, we also found that CXCR3 expression was reduced
on CD3+ T cells in individuals with long-standing diabetes
[19, 20].
Although the changes in CXCR3 expression were only
significant in one of the newly diagnosed cohorts, they
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showed the same downward trend that we observed in the
long-standing diabetes cohorts, along with the same signifi-
cant increases in serum levels of CXCL10 and CXCL11. We
therefore suggest that the lack of statistical significance in one
of the newly diagnosed cohorts was due to a small sample
size, rather than a change in CXCR3 expression limited to
individuals with long-standing diabetes.
CXCR3 is constitutively expressed or readily upregulated on
a substantial proportion of memory B cells [21, 22]. In contrast
to individuals with rheumatoid arthritis or systemic lupus erythe-
matosus [23], we found that expression levels of CD24 and
CXCR3 on switched CD21+CD24+CD27+CD38intCD95+IgD−
memory B cells were reduced in individuals with long-standing
diabetes. These cells are analogous to a highly activated popula-
tion of CD21+CD24+CD27+CD38+CD95+CXCR3+IgD− B
cells, in which decreased expression levels of CD21 and in-
creased expression levels of CD95 and CXCR3 correlate with
activation status [18]. Moreover, they are clearly distinct from
regulatory CD27−CD24hiCD38hi B cells, which are defective
in immune-deficient and other autoimmune conditions [5, 24,
25]. It is also notable that we did not detect increased ex-
pression levels of CD95 on switched memory B cells, as
described previously in individuals with rheumatoid arthritis
[26]. Instead, we found that CD95 expression was reduced
on switched CD27+IgD− memory B cells in individuals with
long-standing diabetes, consistent with the findings of a re-
cent study by Hanley and colleagues, who also reported
lower frequencies of CD24++CD38++ B cells in people with
type 1 diabetes [27]. This latter phenotype is indicative of
regulatory B cells [28], but does not match the profiles we
identified in areas 2 and 6 of the SPADE tree, where re-
duced expression of CD24 was apparent in newly diagnosed
individuals and those with long-standing diabetes. However,
it has been reported that people with asthma have decreased
percentages of CD24+CD27+ B cells, which are required for
the induction of IL10+ T cells [29]. Phenotypically, these
cells would be represented in area 2 of the B cell SPADE
tree, although the physiological function of the decrease in
CD24 expression that we observed is currently unknown.
Serum concentrations of CXCL10 are known to be ele-
vated in individuals with recent-onset type 1 diabetes
[30–32], although there has been one report of decreased
CXCL10 levels in children with type 1 diabetes [33]
(reviewed in [34]). In a longitudinal study of children en-
rolled at diagnosis of type 1 diabetes, significantly higher
CXCL10 levels were found in these participants compared
with healthy control individuals [30]. Serum CXCL10 con-
centrations remained elevated at 1 month post diagnosis
and then declined over the next 9-–30 months, persisting
at levels above those detected in healthy control individuals
[30]. Another study demonstrated that CXCL10 levels in-
crease over time in at-risk individuals, peaking as they
become seropositive for islet autoantibodies, irrespective
of further progression to clinical type 1 diabetes [35]. In
line with these earlier reports, we found increased serum
concentrations of CXCL10 in adults with newly diagnosed
type 1 diabetes and slightly lower levels in adults with
long-standing type 1 diabetes (but elevated compared with
healthy control individuals). We further demonstrated in-
creased serum levels of CXCL11 in adults with type 1
diabetes, irrespective of time from diagnosis. Decreased
expression levels of CXCR3 on memory B cells in indi-
viduals with type 1 diabetes may therefore reflect ligand-
induced receptor internalisation and/or downregulation [36].
However, it has also been shown that reduced expression
of CXCR3 can lead to increased ligand concentrations, as
the receptor has a scavenger function [37]. An alternative
possibility is that memory CXCR3hi B cells traffic to the
pancreas or pancreatic lymph nodes in individuals with
type 1 diabetes, as shown previously for memory T cells
[38, 39]. A similar phenomenon may explain why circulat-
ing switched memory B cells in individuals with type 1
diabetes also express lower levels of the adhesion molecule
CD24.
CXCR3 is widely expressed in the CD3+ compartment,
especially among T helper type 1-polarised CD4+ and ef-
fector CD8+ T cells [40]. In line with previous studies [19,
20], we found reduced expression levels of CXCR3 on
circulating CD3+ T cells in individuals with type 1 diabe-
tes. These findings are compatible with disease-associated
trafficking of CD3+CXCR3hi T cells to the pancreas [19,
20, 33]. In addition, we observed a simultaneous decrease
in CD38 expression on a proportion of these CD3+ T cells.
High levels of CD38 have been described on a subpopula-
tion of peripheral CD4+CD25+CD127dim regulatory T
cells, which are sensitive to therapeutic intervention with the
CD38-specific monoclonal antibody daratumumab in individ-
uals with multiple myeloma [41]. It has also been reported that
CD8+CXCR3+ T cells exert regulatory functions in humans
[42]. Alternatively, the CD27+CD38+CD95+CXCR3+ T cell
population found in area 4 may represent a stem cell-like
memory (TSCM) subset [43]. It is notable in this regard that
autoantibodies specific for CD38 have been detected in
individuals with type 1 diabetes [44].
In addition to CXCL10 and CXCL11, our analysis of se-
rum chemokines and cytokines revealed elevated concentra-
tions of BAFF in individuals with long-standing diabetes.
This cytokine plays a key role in the development of diabetes
in NOD mice [45, 46], and previous studies have reported
increased serum levels of BAFF in individuals with autoim-
mune thyroid diseases [47] and rheumatoid arthritis [48].
Decreased expression of the BAFF receptor has also been
reported on B cells in children with type 1 diabetes [15].
Intriguingly, BAFF has been shown to enhance the chemotax-
is of primary human B cells in response to a variety of
chemokines [16]. A disease-relevant synergy may therefore
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exist in the setting of type 1 diabetes among raised levels of
BAFF, CXCL10 and CXCL11.
Future studies will focus on investigating the ability of
B cells from individuals with type 1 diabetes to migrate in
response to physiological levels of CXCL10 and CXCL11,
in the presence and absence of BAFF. It will be important
to ascertain whether abnormal blood glucose and insulin
levels in individuals with type 1 diabetes contribute to the
loss of CXCR3 on memory B cells by studying the effects
of ex-vivo culture and by correlating HbA1c values with
chemokine and chemokine receptor expression levels. It is
notable in this context that glycosylation of the extracellu-
lar domains may increase signalling via CXCR3 [49]. A
detailed study of postmortem pancreatic histological sam-
ples, available from the nPOD collection, may allow the
identification of CXCR3++ B cells that trafficked to the
pancreas during life, and were thus lost from the periphery.
Similarly, the source of raised CXCR3 ligands in the serum
remains unknown. Although there is some evidence that
the inflamed pancreas can produce CXCR3 ligands in in-
dividuals with type 1 diabetes [39], it is also possible that
these chemokines are produced in response to elevated
glucose levels in the periphery, an effect that could be
determined by longitudinal measurements of chemokine
levels in conjunction with measurements of HbA1c.
In conclusion, we have identified a mechanistically co-
hesive immune profile associated with type 1 diabetes.
The key abnormalities suggest long-term disruption of a
chemokine ligand/receptor system that controls B cell mi-
gration. On this basis, we propose that related parameters
may find utility as cellular and/or soluble biomarkers to
monitor and/or predict the development of islet-specific
autoantibody responses.
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